Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRI-001 in no-option chronic limb-threatening ischemia due to peripheral arterial disease
2024-517765-16-00Phase 2Authorised
- Sponsor
- Ferring Ventures
- Start
- Apr 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans and chronic limb-threatening ischemia (CLTI) comparing TRI-001 with Placebo comparator (2 arms). Primary endpoints: Safety profile and Percentage change from baseline of target wound size at Month 12. Planned start Apr 2025; status: authorised.
02
Drugs
TRI-001
03
Conditions
arteriosclerosis obliteranschronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2024-517765-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517765-16-00.